Zolbetuximab — now with the brand name Vyloy — is a monoclonal antibody to treat patients with advanced gastric and ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

These medications have been associated with a 40 percent reduction in opioid overdose and 50 percent lower rate of alcohol intoxication.

Tirzepatide was first approved by the Food and Drug Administration ... only options when it comes to weight loss or diabetes, and signficantly more affordable FDA-approved options do exist.

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

(The Hill) – Federal regulators shook up the booming weight loss drug marketplace ... Tirzepatide was first approved by the Food and Drug Administration (FDA) in 2022 and has no generic versions ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...